PAR PHARM
GenericsPAR PHARM is a generic drug manufacturer focused on Dermatology, Infectious Disease, Cardiovascular.
PAR PHARM's Key Drugs
PAR PHARM's core commercial portfolio centers on DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, SAXAGLIPTIN, spanning Dermatology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
PAR PHARM's Recent FDA Approvals
New NDA/BLA approvals for PAR PHARM over the last two years — novel drugs only, excluding generics and label supplements.
PAR PHARM's Therapeutic Areas
PAR PHARM's approved drugs and pipeline span 3 therapeutic areas, led by Dermatology and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PAR PHARM's Top Competitors
PAR PHARM's closest competitors by therapeutic-area and drug-target overlap include Baxter, B BRAUN, and BAUSCH AND LOMB INC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PAR PHARM Pipeline Snapshot
PAR PHARM has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1971-11-30
- Latest
- 2020-12-23
- Applications
- 91